Efficacy and Safety of Vatelizumab in Patients With Relapsing-Remitting Multiple Sclerosis

NCT02222948 · clinicaltrials.gov ↗
PHASE2
Phase
TERMINATED
Status
112
Enrollment
INDUSTRY
Sponsor class

Stopped Study discontinued based on planned interim analysis of the primary endpoint. Not linked to any safety concern.

Conditions

Interventions

Sponsor

Genzyme, a Sanofi Company